Recent clinical studies on lipo-PGE1 and lipo-PGI2: PGE1 and PGI2 incorporated in lipid microspheres, for targeted delivery
- 1 January 1994
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 28 (1-3) , 243-249
- https://doi.org/10.1016/0168-3659(94)90171-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Amelioration of nerve Na(+)-K(+)-ATPase activity independently of myo-inositol level by PGE1 analogue OP-1206.alpha-CD in streptozocin-induced diabetic ratsDiabetes, 1991
- Lipo-prostaglandin preparationsProstaglandins, Leukotrienes & Essential Fatty Acids, 1991
- Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesionsProstaglandins, Leukotrienes & Essential Fatty Acids, 1990
- A preliminary double-blind cross-over trial of lio-PGI2, A prostacyclin derivative incorporated in lipid microspheres, in cerebral infarctionProstaglandins, 1990
- The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis modelHepatology, 1987
- Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspheresProstaglandins, 1987
- Prostacyclin infusion in acute cerebral infarctionNeurology, 1984
- Treatment of ischaemic stroke with prostacyclin.Stroke, 1983
- Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion.Annals of the Rheumatic Diseases, 1982
- Protective effects of 16,16-dimethyl PGE2 on the liver and kidneyProstaglandins, 1981